Article Text

PDF
AB0460 Remission After Discontinuation of Abatacept for Good Response: Results from the ORA Registry
  1. F. Sagez1,
  2. P. Ravaud2,
  3. N. Afif3,
  4. A. Benmansour4,
  5. A. Constantin5,
  6. E. Dernis6,
  7. M. Dougados7,
  8. R.M. Flipo8,
  9. B. Jamard5,
  10. J.L. Legrand9,
  11. J. Morel10,
  12. S. Redeker11,
  13. C. Richez12,
  14. C. Scotto13,
  15. E. Solau-Gervais14,
  16. I. Pane2,
  17. X. Mariette15,
  18. J.E. Gottenberg1
  19. on behalf of the French Society of Rheumatology
  1. 1Rheumatology, Strasbourg University Hospital, Strasbourg
  2. 2Clinical epidemiology, Hôtel-Dieu Hospital, Paris
  3. 3Rheumatology, University Hospital, Mulhouse
  4. 4Rheumatology, University Hospital, Chateauroux
  5. 5Rheumatology, University Hospital, Toulouse
  6. 6Rheumatology, University Hospital, LEMANS
  7. 7Rheumatology, Cochin Hospital, Paris
  8. 8Rheumatology, University Hospital, Lille
  9. 9Rheumatology, Riaumont Hospital, Lievin
  10. 10Rheumatology, University Hospital, Montpellier
  11. 11Rheumatology, University Hospital, Abbeville
  12. 12Rheumatology, University Hospital, Bordeaux
  13. 13Rheumatology, University Hospital, Perpignan
  14. 14Rheumatology, University Hospital, Poitiers
  15. 15Rheumatology, Paris Sud University, Paris, France

Abstract

Background Discontinuation of biologics is sometimes possible in recent-onset rheumatoid arthritis, but has not been evaluated in established rheumatoid arthritis.

Objectives The objective of the study was to determine the proportion of discontinuation of abatacept for remission, characteristics of patients in remission and duration of biologic-free remission.

Methods The ORA registry has included 1024 patients to study tolerance, efficacy, and drug retention of abatacept prospectively for 5 years.

992 patients had at least 1 follow-up visit. The reasons of discontinuation of abatacept are collected in the electronic CRF, as well as the initiation of a new biologic. The charts of patients having discontinued abatacept for remission for more than twelve months without initiation of a new biologic were analyzed.

Results 10 patients (1.0/% of patients) discontinued abatacept for more than 12 months because of persistent remission. The discontinuation of abatacept was related to remission only (n=6 patients), remission and pulmonary infection (n=1), remission and occurrence of a monoclonal gammapathy (n=1) and remission and pregnancy (n=2). The median disease duration of rheumatoid arthritis before abatacept was 6 (1; 21) years. Nine of the 10 patients were positive for rheumatoid factor and/or anti-CCP.

The patients had previously received a median of 1.5 (0;4) synthetic DMARDs and 1.5 (0;3) biologics. 7 patients received methotrexate concomitantly to abatacept. Median DAS 28 was 3.9 (2.5; 8.7) before abatacept.

Median duration of treatment with abatacept was 25 (8;40) months with a median of 26 (7;42) infusions. The median duration of remission without a new biologic was 29.5 (12; 39) months.

No biologic was reinitiated in 6 of the 10 patients, abatacept was reinitiated in 2 patients and tocilizumab was initiated in 2 patients.

Conclusions These results of the ORA registry demonstrate that only 1% of the patients included in the ORA registry discontinued abatacept for persistent remission. These patients had classical seropositive RA (9/10 patients).

In this study, this remission was persistent without any new biologic in 6 out of the 10 patients.

In half of the patients approximately, the discontinuation was not only related to the efficacy of the treatment but also to adverse event or pregnancy. Such life circumstances may give us the opportunity to try to discontinue abatacept in responders.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.